BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim HowardBusiness Wire • 05/20/26
BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell LymphomaBusiness Wire • 05/13/26
BeOne Medicines Announces First Quarter 2026 Financial Results and Business UpdatesBusiness Wire • 05/06/26
U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEABusiness Wire • 04/29/26
Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 EarningsZacks Investment Research • 02/26/26
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology LeadershipBusiness Wire • 02/26/26
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26Business Wire • 02/11/26
BeOne Medicines AG (ONC) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/13/26
Is the Options Market Predicting a Spike in BeOne Medicines Stock?Zacks Investment Research • 01/07/26
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEABusiness Wire • 01/06/26
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/23/25
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular CarcinomaBusiness Wire • 12/18/25
Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold TumorsPRNewsWire • 12/10/25
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic LeukemiaBusiness Wire • 12/08/25
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell MalignanciesBusiness Wire • 12/07/25